{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:14:24Z","timestamp":1780362864509,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.nefro.2020.07.002","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T07:59:51Z","timestamp":1601971191000},"page":"585-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metabol\u00f3mica de la nefropat\u00eda diab\u00e9tica: tras la huella de indicadores de desarrollo y progresi\u00f3n"],"prefix":"10.1016","volume":"40","author":[{"given":"Paula","family":"Cordero-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"S\u00e1nchez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Alberto","family":"Garc\u00eda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma L.","family":"Saucedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2020.07.002_bib0215","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2020.07.002_bib0220","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.nefro.2020.07.002_bib0225","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD: conclusions from a \u2018Kidney Disease: Improving Global Outcomes\u2019 (KDIGO) Controversies Conference","volume":"90","author":"Perkovic","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.07.002_bib0230","series-title":"Prevalencia de Incidencia de la ERC en TRR en Am\u00e9rica Latina. Informe","year":"2014"},{"key":"10.1016\/j.nefro.2020.07.002_bib0235","unstructured":"Tamayo Orozco J, Lastiri Quir\u00f3s S. La enfermedad renal cr\u00f3nica en M\u00e9xico. M\u00e9xico: Consejo Nacional de Ciencia y Tecnolog\u00eda; Academia Nacional de Medicina, CONACYT; 2016."},{"key":"10.1016\/j.nefro.2020.07.002_bib0240","series-title":"Diabetes country profiles","year":"2016"},{"key":"10.1016\/j.nefro.2020.07.002_bib0245","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.nefro.2020.07.002_bib0250","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/ki.2010.550","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts","volume":"79","author":"Astor","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.07.002_bib0255","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.kint.2016.09.037","article-title":"Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality","volume":"91","author":"Carrero","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.07.002_bib0260","first-page":"324","article-title":"[Comparison of four methods for measuring glomerular filtration rate by inulin clearance in healthy individuals and patients with renal failure]","volume":"30","author":"Hernandez Ocampo","year":"2010","journal-title":"Nefrolog\u00eda."},{"key":"10.1016\/j.nefro.2020.07.002_bib0265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/kisup.2012.77","article-title":"Summary of Recommendation Statements","volume":"3","year":"2013","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.nefro.2020.07.002_bib0270","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jama.2015.0602","article-title":"Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review","volume":"313","author":"Levey","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2020.07.002_bib0275","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/jcm8101543","article-title":"The error of estimated GFR in type 2 diabetes mellitus","volume":"8","author":"Luis-Lima","year":"2019","journal-title":"J Clin Med."},{"key":"10.1016\/j.nefro.2020.07.002_bib0280","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/ndt\/gfv364","article-title":"The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease","volume":"31","author":"Cisek","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2020.07.002_bib0285","doi-asserted-by":"crossref","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","article-title":"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker","volume":"7","author":"Ju","year":"2015","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.nefro.2020.07.002_bib0290","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MNH.0000000000000278","article-title":"Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases","volume":"25","author":"Magalhaes","year":"2016","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.nefro.2020.07.002_bib0295","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ki.2013.328","article-title":"Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease","volume":"85","author":"Posada-Ayala","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.07.002_bib0300","article-title":"Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nefro.2020.07.002_bib0305","doi-asserted-by":"crossref","first-page":"26138","DOI":"10.1038\/srep26138","article-title":"Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling","volume":"6","author":"Kimura","year":"2016","journal-title":"Sci Rep."},{"key":"10.1016\/j.nefro.2020.07.002_bib0310","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med."},{"key":"10.1016\/j.nefro.2020.07.002_bib0315","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cmet.2016.09.018","article-title":"Metabolomics and metabolic diseases: where do we stand?","volume":"25","author":"Newgard","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.nefro.2020.07.002_bib0320","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrm.2016.25","article-title":"Metabolomics: beyond biomarkers and towards mechanisms","volume":"17","author":"Johnson","year":"2016","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0325","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.copbio.2016.08.001","article-title":"The future of NMR-based metabolomics","volume":"43","author":"Markley","year":"2017","journal-title":"Curr Opin Biotechnol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.csbj.2016.02.005","article-title":"A guide to the identification of metabolites in NMR-based metabonomics\/metabolomics experiments","volume":"14","author":"Dona","year":"2016","journal-title":"Comput Struct Biotechnol J."},{"key":"10.1016\/j.nefro.2020.07.002_bib0335","first-page":"92","article-title":"Multivariate analysis in metabolomics","volume":"1","author":"Worley","year":"2013","journal-title":"Curr Metabolomics."},{"key":"10.1016\/j.nefro.2020.07.002_bib0340","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ejps.2017.05.018","article-title":"Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine","volume":"109","author":"Kohler","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"10.1016\/j.nefro.2020.07.002_bib0345","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1681\/ASN.2018030256","article-title":"Metabolomics research in chronic kidney disease","volume":"29","author":"Grams","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0350","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.2174\/0929867325666180307110908","article-title":"Chronic kidney disease and the search for new biomarkers for early diagnosis","volume":"25","author":"Saucedo","year":"2018","journal-title":"Curr Med Chem."},{"key":"10.1016\/j.nefro.2020.07.002_bib0355","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrneph.2017.30","article-title":"Metabolomics for clinical use and research in chronic kidney disease","volume":"13","author":"Hocher","year":"2017","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0360","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1752-8062.2012.00437.x","article-title":"A pilot metabolic profiling study in serum of patients with chronic kidney disease based on (1)H-NMR-Spectroscopy","volume":"5","author":"Qi","year":"2012","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.nefro.2020.07.002_bib0365","doi-asserted-by":"crossref","first-page":"e96955","DOI":"10.1371\/journal.pone.0096955","article-title":"Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease","volume":"9","author":"Nkuipou-Kenfack","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.nefro.2020.07.002_bib0370","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.kint.2016.01.014","article-title":"Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events","volume":"89","author":"Kim","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.07.002_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0213764","article-title":"Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: Results from the Progredir Cohort","volume":"14","author":"Titan","year":"2019","journal-title":"PLoS One."},{"key":"10.1016\/j.nefro.2020.07.002_bib0380","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2337\/dc16-0173","article-title":"Circulating modified metabolites and a risk of ESRD in patients with type 1 diabetes and chronic kidney disease","volume":"40","author":"Niewczas","year":"2017","journal-title":"Diabetes Care."},{"key":"10.1016\/j.nefro.2020.07.002_bib0385","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000447954","article-title":"Metabolomics in diabetic kidney disease: unraveling the biochemistry of a silent killer","volume":"44","author":"Darshi","year":"2016","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0390","doi-asserted-by":"crossref","first-page":"W486","DOI":"10.1093\/nar\/gky310","article-title":"MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis","volume":"46","author":"Chong","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.nefro.2020.07.002_bib0395","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/metabo7030046","article-title":"Metabolomics analysis of urine samples from children after acetaminophen overdose","volume":"7","author":"Schnackenberg","year":"2017","journal-title":"Metabolites."},{"key":"10.1016\/j.nefro.2020.07.002_bib0400","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00592-018-1213-0","article-title":"Optimization of kidney dysfunction prediction in diabetic kidney disease using targeted metabolomics","volume":"55","author":"Ibarra-Gonz\u00e1lez","year":"2018","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0410","doi-asserted-by":"crossref","unstructured":"Hirayama A, Nakashima E, Sugimoto M, Akiyama S, Sato W, Maruyama S, et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem. 2012;404:3101\u20139.","DOI":"10.1007\/s00216-012-6412-x"},{"key":"10.1016\/j.nefro.2020.07.002_bib0405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cca.2016.05.018","article-title":"Changes in serum metabolites with the stage of chronic kidney disease: Comparison of diabetes and non-diabetes","volume":"459","author":"Lee","year":"2016","journal-title":"Clin Chim Acta."},{"key":"10.1016\/j.nefro.2020.07.002_bib0415","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1681\/ASN.2013020126","article-title":"Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease","volume":"24","author":"Sharma","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0420","doi-asserted-by":"crossref","unstructured":"Han LD, Xia JF, Liang QL, Wang Y, Wang YM, Hu P, et al. Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal Chim Acta. 2011;689:85\u201391.","DOI":"10.1016\/j.aca.2011.01.034"},{"key":"10.1016\/j.nefro.2020.07.002_bib0425","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/dme.12447","article-title":"Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus","volume":"31","author":"Pena","year":"2014","journal-title":"Diabet Med."},{"key":"10.1016\/j.nefro.2020.07.002_bib0430","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000446484","article-title":"Metabolomics of chronic kidney disease progression: a case-control analysis in the Chronic Renal Insufficiency Cohort Study","volume":"43","author":"Rhee","year":"2016","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2020.07.002_bib0435","doi-asserted-by":"crossref","unstructured":"Saulnier PJ, Darshi M, Wheelock KM, Looker HC, Fufaa GD, Knowler WC, et al. Urine metabolites are associated with glomerular lesions in type 2 diabetes. Metabolomics, 2018;14:84.","DOI":"10.1007\/s11306-018-1380-6"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699520301193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699520301193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:56Z","timestamp":1759323236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699520301193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0211699520301193"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2020.07.002","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabol\u00f3mica de la nefropat\u00eda diab\u00e9tica: tras la huella de indicadores de desarrollo y progresi\u00f3n","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2020.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}